Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	24.78	65.63	-6.69	-94.62	-51.16	-26.52
Depreciation & Amortization	3.79	3.77	2.84	1.9	1.12	0.33
Loss (Gain) From Sale of Assets	-	-	-	-	0.07	0.02
Loss (Gain) From Sale of Investments	-9.32	-10.02	-5.78	0.15	-	-
Stock-Based Compensation	19.27	17.92	13.11	9.9	2.53	0.33
Change in Accounts Receivable	75.47	2.2	-5.88	-	-	-
Change in Accounts Payable	-0.26	0.99	-2.81	5.29	-0.72	0.63
Change in Unearned Revenue	-156.22	-119.81	139.98	-	-	-
Change in Income Taxes	-5.05	-3.36	4.02	-	-	-
Change in Other Net Operating Assets	-7	1.12	1	-16.4	-2.71	-0.35
Operating Cash Flow	-54.55	-41.56	139.8	-93.79	-50.86	-25.57
Capital Expenditures	-3.46	-3.16	-5.61	-2.89	-4.58	-2.32
Investment in Securities	-45.7	-24.64	-132.78	-145.76	-	-
Investing Cash Flow	-49.16	-27.8	-138.4	-148.65	-4.58	-2.32
Issuance of Common Stock	103.11	102.96	21.04	0.48	191.63	0.25
Financing Cash Flow	103.11	102.96	21.04	0.48	307.46	50.09
Net Cash Flow	-0.6	33.61	22.45	-241.96	252.02	22.2
Free Cash Flow	-58.01	-44.72	134.19	-96.67	-55.44	-27.89
Free Cash Flow Margin	-33.68%	-21.21%	104.01%	-	-	-
Free Cash Flow Per Share	-1.43	-1.15	4.06	-3.09	-8.85	-25.23
Cash Income Tax Paid	4.62	4.62	14.72	-	-	-
Levered Free Cash Flow	-65.48	-73.29	149.04	-58.56	-36.26	-17.21
Unlevered Free Cash Flow	-65.48	-73.29	149.04	-58.56	-36.26	-17.21
Change in Net Working Capital	87.64	121.2	-140.68	6.68	3.37	-1.13

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q